Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of HM71224 in healthy adult male volunteers
NL-OMON40064Phase 1Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of poseltinib in rheumatoid arthritis (RA) and chronic inflammatory conditions (14 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Safety and tolerability and Maximum tolerated dose. Started Jan 2013; status: active, not recruiting.
02
Drugs
poseltinib
03
Conditions
rheumatoid arthritis (RA)chronic inflammatory conditions
Beyond the preview
Go deeper on NL-OMON40064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40064.